References
- D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95: 281–6
- Carter CA, Donohue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 2003; 21: 4001–8
- Schröder FH. Screening for prostate cancer. Urol Clin North Am 2003; 30: 239–51
- Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Häggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347: 781–9
- Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–80
- Read WL, Tierney RM, Page NC, Costas I, Govindan R, Spitznagel EL, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22: 3099–103
- Piccirillo JF. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology (Huntingt) 1995; 9: 831–6
- Paleri V, Wight RG, Davies GR. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck 2003; 25: 1019–26
- Sobin LH, Wittekind C, editors. TNM classification of malignant tumours, 3rd ed. New York: Wiley-Liss; 2002.
- Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17: 292–306
- Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG. Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001; 91: 2302–14
- Froehner M, Koch R, Litz R, Oehlschlaeger S, Noack B, Manseck A, et al. Preoperative cardiopulmonary risk assessment as predictor of early non-cancer and overall mortality after radical prostatectomy. Urology 2003; 61: 596–600
- Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology 2003; 62: 698–701
- Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP. Which conditions contributing to the Charlson score predict survival after radical prostatectomy?. J Urol 2004; 171: 697–9
- Froehner M, Koch R, Litz RJ, Oehlschlaeger S, Hakenberg OW, Wirth MP. Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy. Eur Urol 2005; 47: 190–5
- Available from: www.asahq.org/Profinfo/PhysicalStatus.html.
- Available from: www.cochranefoundation.com/docs/nyha-class.htm.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–83
- Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH. The process for continuous improvement of the TNM classification. Cancer 2004; 100: 1–5
- Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441–7
- Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol 2002; 168: 525–9
- Tewari A, Hasan M, Devine G, Menon M. What actually determines the mortality in men with prostate cancer? [abstract]. J Urol 2004; 171(Suppl)124
- Clemens JD, Feinstein AR, Holabird N, Cartwright S. A new clinical-anatomic staging system for evaluating prognosis and treatment of prostate cancer. J Chron Dis 1986; 11: 913–28